OBJECTIVES: The present study sought to determine the value of fractional flow reserve (FFR) compared with stress perfusion scintigraphy (SPS) in patients with recent unstable angina/non-ST-segment elevation myocardial infarction (UA/NSTEMI). BACKGROUND:Fractional flow reserve, an invasive index of stenosis severity, is a reliable surrogate for SPS in patients with normal left ventricular function. An FFR > or = 0.75 can distinguish patients after myocardial infarction (MI) with a positive SPS from those with a negative SPS. However, the use of FFR has not been investigated after UA/NSTEMI. METHODS:Seventy patients who had recent UA/NSTEMI and an intermediate single-vessel stenosis were randomized to either SPS (n = 35) or FFR (n = 35). Patients in the SPS group were discharged if the SPS revealed no ischemia, whereas those in the FFR group were discharged if the FFR was > or = 0.75. Patients with a positive SPS and those with an FFR <0.75 underwentpercutaneous transluminal coronary angioplasty. The use of FFR markedly reduced the duration and cost of hospitalization compared with SPS (11 +/- 2 h vs. 49 +/- 5 h [-77%], p < 0.001; and 1,329 US dollars +/- 44 US dollars vs. 2,113 US dollars +/- 120 US dollars, respectively, p < 0.05). There were no significant differences in procedure time, radiation exposure time, or event rates during follow-up, including death, MI, or revascularization. CONCLUSIONS: These data indicate that: 1) the use of FFR in patients with recent UA/NSTEMI markedly reduces the duration and cost of hospitalization compared with SPS; and 2) these benefits are not associated with an increase in procedure time, radiation exposure time, or clinical event rates.
RCT Entities:
OBJECTIVES: The present study sought to determine the value of fractional flow reserve (FFR) compared with stress perfusion scintigraphy (SPS) in patients with recent unstable angina/non-ST-segment elevation myocardial infarction (UA/NSTEMI). BACKGROUND: Fractional flow reserve, an invasive index of stenosis severity, is a reliable surrogate for SPS in patients with normal left ventricular function. An FFR > or = 0.75 can distinguish patients after myocardial infarction (MI) with a positive SPS from those with a negative SPS. However, the use of FFR has not been investigated after UA/NSTEMI. METHODS: Seventy patients who had recent UA/NSTEMI and an intermediate single-vessel stenosis were randomized to either SPS (n = 35) or FFR (n = 35). Patients in the SPS group were discharged if the SPS revealed no ischemia, whereas those in the FFR group were discharged if the FFR was > or = 0.75. Patients with a positive SPS and those with an FFR <0.75 underwent percutaneous transluminal coronary angioplasty. The use of FFR markedly reduced the duration and cost of hospitalization compared with SPS (11 +/- 2 h vs. 49 +/- 5 h [-77%], p < 0.001; and 1,329 US dollars +/- 44 US dollars vs. 2,113 US dollars +/- 120 US dollars, respectively, p < 0.05). There were no significant differences in procedure time, radiation exposure time, or event rates during follow-up, including death, MI, or revascularization. CONCLUSIONS: These data indicate that: 1) the use of FFR in patients with recent UA/NSTEMI markedly reduces the duration and cost of hospitalization compared with SPS; and 2) these benefits are not associated with an increase in procedure time, radiation exposure time, or clinical event rates.
Authors: Marcus Hacker; Johannes Rieber; Rupert Schmid; Christian Lafougere; Andreas Tausig; Karl Theisen; Volker Klaus; Reinhold Tiling Journal: J Nucl Cardiol Date: 2005 Nov-Dec Impact factor: 5.952
Authors: Katia Orvin; Tamir Bental; Alon Eisen; Hana Vaknin-Assa; Abid Assali; Eli I Lev; David Brosh; Ran Kornowski Journal: Cardiovasc Diagn Ther Date: 2013-09
Authors: Stefan Förster; Johannes Rieber; Christopher Ubleis; Mayo Weiss; Peter Bartenstein; Paul Cumming; Volker Klauss; Marcus Hacker Journal: Int J Cardiovasc Imaging Date: 2009-09-16 Impact factor: 2.357
Authors: Colin Berry; Jamie Layland; Arvind Sood; Nick P Curzen; Kanarath P Balachandran; Raj Das; Shahid Junejo; Robert A Henderson; Andrew H Briggs; Ian Ford; Keith G Oldroyd Journal: Am Heart J Date: 2013-08-27 Impact factor: 4.749
Authors: Shriti Masrani Mehta; Jeremiah P Depta; Eric Novak; Jayendrakumar S Patel; Yogesh Patel; David Raymer; Gabrielle Facey; Alan Zajarias; John M Lasala; Jasvindar Singh; Richard G Bach; Howard I Kurz Journal: J Am Heart Assoc Date: 2015-08-19 Impact factor: 5.501